Evidence map›Paper›PMID 38724531›Full record

Observational studyNature communications2024

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.

Sooyeon Kho, Kwonjune J Seung, Helena Huerga, Mathieu Bastard, Palwasha Y Khan, Carole D Mitnick, Michael L Rich, Shirajul Islam, Dali Zhizhilashvili, Lusine Yeghiazaryan and 14 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03259269 (endTB), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03259269 completednot on this map

endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid

TypeobservationalSponsorPartners in HealthRan2015 to 2019Enrolled2,804ConditionsTuberculosis, Multidrug-ResistantArmsThis is a non-intervention observational study
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sooyeon KhoDivision of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.
Kwonjune J SeungDivision of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.
Helena HuergaEpicentre, 14-34 Avenue Jean Jaurès, Paris, France.
Mathieu BastardEpicentre, 14-34 Avenue Jean Jaurès, Paris, France.
Palwasha Y KhanDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.
Carole D MitnickDivision of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.
Michael L RichDivision of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.
Shirajul IslamInteractive Research and Development, Dhaka, Bangladesh.
Dali ZhizhilashviliMédecins sans Frontières, Tbilisi, Georgia.
Lusine YeghiazaryanNational Center for Pulmonology, Yerevan, Armenia.
Elena Nikolaevna NikolenkoRepublican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
Khin ZarliMédecins sans Frontières, Yangon, Myanmar.
Sana AdnanIndus Hospital and Health Network, Karachi, Pakistan.
Naseem SalahuddinIndus Hospital and Health Network, Karachi, Pakistan.
Saman AhmedInteractive Research and Development, Karachi, Pakistan.
Zully Haydee Ruíz VargasMaria Auxiliadora Hospital, San Juan de Miraflores, Peru.
Amsalu BekeleDepartment of Internal Medicine, Tikur Anbessa Specialized Hospital and Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Aiman ShaimerdenovaKaraganda Regional Center of Phthisiopulmonology, Karaganda, Kazakhstan.
Meseret TamiratPartners in Health, Lesotho, Maseru, Lesotho.
Alain GelinZanmi Lasante, Port-au-Prince, Haiti.
Stalz Charles VilbrunHaitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
Catherine Hewison *Medical Department, Médecins sans Frontières, Paris, France.
Uzma Khan *Interactive Research and Development Global, Singapore, Singapore.
Molly Franke *Partners in Health, 800 Boylston Street Suite 300, Boston, MA, USA. molly_franke@hms.harvard.edu.ORCID http://orcid.org/0000-0002-4890-5728

Funding

Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methodsR01AI146095 · NIAID · HARVARD MEDICAL SCHOOL · PI FRANKE, MOLLY FORREST · 2020 to 2024
$3.6M
NIAID NIH HHS R01 AI146095
6 · The paper itself

Abstract

Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT03259269) to estimate the frequency (primary endpoint) among individuals receiving a longer (18-to-20 month) regimen for multidrug- or rifampicin-resistant (MDR/RR) TB who experienced culture conversion. We also conduct Cox proportional hazard regression analyses to identify factors associated with reversion, including comorbidities, previous treatment, cavitary disease at conversion, low body mass index (BMI) at conversion, time to conversion, and number of likely-effective drugs. Of 1,286 patients, 54 (4.2%) experienced reversion, a median of 173 days (97-306) after conversion. Cavitary disease, BMI < 18.5, hepatitis C, prior treatment with second-line drugs, and longer time to initial culture conversion were positively associated with reversion. Reversion was uncommon. Those with cavitary disease, low BMI, hepatitis C, prior treatment with second-line drugs, and in whom culture conversion is delayed may benefit from close monitoring following conversion.

Indexed as

Antitubercular AgentsDiarylquinolinesNitroimidazolesOxazolesSputumTuberculosis, Multidrug-ResistantAdultDrug RepositioningFemaleHumansMaleMiddle AgedMycobacterium tuberculosisProspective StudiesAntitubercular AgentsbedaquilineDiarylquinolinesNitroimidazolesOPC-67683Oxazoles

Identifiers

PMID38724531
PMCPMC11082252

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.